Topical Quinic Acid Composition for Skin Inflammation Signs

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing cosmetic solutions fail to effectively prevent or slow down the unsightly signs of skin and scalp inflammation, particularly in sensitive and reactive skin, caused by factors such as temperature changes, chemicals, and microbial imbalances.

Innovation Solution

A composition comprising poly-substituted quinic acid derivatives, derived from burdock root extracts, is used in a topical formulation with a specific ratio of organic solvents and water, applied through a process of aeroponic cultivation, to provide hydration and reduce inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cosmetic solutions are used, then skin appearance is maintained, but inflammation signs (redness) cannot be effectively prevented or slowed down

Engineering Contradiction:
Improveeffectiveness in preventing inflammation signsVSAvoidinflammation signs (redness)
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical composition parameters by using poly-substituted quinic acid derivatives with specific molecular structures (formula I) containing caffeoyl and maloyl radicals. These chemical parameter changes enable the composition to effectively inhibit inflammatory cytokines and regulate skin microbiota, thereby preventing inflammation signs that conventional cosmetics cannot achieve.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite active ingredient system combining multiple poly-substituted quinic acid derivatives (formula I compounds) with specific ratios of organic solvents (1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 1,3-butanediol, 1,2-butanediol, 2-methyl-2,4-pentanediol, 1,6-hexanediol, 1,8-octanediol) and water. This composite formulation synergistically regulates skin microbiota and inhibits inflammatory cytokines, achieving effective prevention of inflammation signs.

Inventive Principle:
Principle #40Composite materials

2Reliability

If the skin acts as an interface organ protecting the internal environment, then barrier function is maintained, but the skin is subjected to numerous daily stresses from external environment

Engineering Contradiction:
Improvebarrier functionVSAvoidexternal stresses (temperature, chemicals, microbiota)
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The composition performs preliminary protective action by pre-regulating skin microbiota and pre-inhibiting inflammatory cytokines before external stresses can cause damage. The poly-substituted quinic acid derivatives actively prevent the development of inflammation signs in response to temperature changes, chemical contacts, and microbial imbalances, thereby maintaining barrier function against external environment stresses.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If stratum corneum is the first layer to undergo external stresses, then protection is provided, but signs of inflammation and redness develop following stressors

Engineering Contradiction:
Improveprotection against external stressesVSAvoidinflammation signs (redness) following stressors
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The composition establishes a feedback mechanism where poly-substituted quinic acid derivatives continuously monitor and respond to skin stressors. The active ingredients detect changes in skin condition following external stresses and actively inhibit the development of inflammation signs and redness, creating a dynamic protective system that maintains skin appearance even when subjected to temperature changes, chemicals, or mechanical stresses.

Inventive Principle:
Principle #23Feedback

Data Source

PatentEP3773443B1Composition for preventing or slowing the appearance of signs of inflammation
Publication Date: 2026.03.11 SOC DEXPLOITATION DE PROD POUR LES IND CHEM SEPPIC
  • EP3773443B1 patent drawing
  • EP3773443B1 patent drawing
  • EP3773443B1 patent drawing

AI summary

Disclosed is the use of a composition (C1) for preventing or slowing the appearance of unaesthetic signs associated with inflammation of the skin and/or scalp, or of eliminating such signs, said composition (C1) comprising, per 100% by mass: a) - from 60.0% by mass to 75.0% by mass of an organic solvent (SO) chosen from 1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 1,3-butanediol, 1,2-butanediol, 2-methyl-2,4-pentanediol, 1,6-hexanediol, 1,8-octanediol, or a blend of the above compounds; b) - from 0.1 % by mass to 2.0% by mass of a composition (ES) comprising a mass quantity x1, expressed as mass equivalent of 1-O-(2-caffeyol) maloyl-3,5-O-dicaffeoylquinic acid, greater than or equal to 200 mg/g of at least one compound of general formula (I): in which Q1, Q 2, Q 3, Q 4 et Q independently of each other represent the hydroxyl radical or one of its salts or a radical selected among the caffeoyl, maloyl, caffeoyl maloyl and maloyl caffeoyl radicals, it being understood that at least one of these radicals Q1, Q 2, Q 3, Q 4 et Q represents neither the -OH radical nor one of its salts; and c) from 20.0% by mass to 35.0% by mass water.